AbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month High – What’s Next?

AbCellera Biologics Inc. (NASDAQ:ABCL) shares reached a new 52-week high on Monday . The company traded as high as $9.01 and last traded at $8.83, with a volume of 8136002 shares. The stock had previously closed at $6.93.

AbCellera Biologics News Roundup

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Positive Phase 2 results validate ABCL635: The experimental non-hormonal menopause treatment met its primary efficacy endpoints and significantly reduced the frequency and severity of moderate-to-severe hot flashes. The results are being viewed as a potential efficacy benchmark and represent AbCellera’s first meaningful pipeline win, improving investor confidence in its ability to develop proprietary medicines. Reuters article
• Positive Sentiment: Analyst sharply raises valuation target: Truist Financial upgraded its price target from $12 to $30 while maintaining a “Buy” rating, signaling substantial upside potential if ABCL635 advances successfully and the company’s pipeline gains commercial traction. Benzinga article
• Positive Sentiment: Bullish trading activity increased: Investors purchased 16,666 ABCL call options, approximately 151% above typical daily volume. While not a fundamental development, the activity indicates heightened speculative interest following the clinical announcement. Options trading article
• Neutral Sentiment: Investors are reassessing the company’s growth story: Coverage broadly agrees that the menopause data are strong, but the longer-term opportunity depends on whether ABCL635 can progress through later-stage testing and whether AbCellera can produce additional successful proprietary programs.
• Negative Sentiment: Proposed $200 million offering creates dilution risk: AbCellera launched an underwritten offering of common shares and pre-funded warrants. The capital would strengthen its balance sheet and fund development, but issuing new securities may dilute existing shareholders and pressure the stock in the near term. AbCellera offering announcement
• Negative Sentiment: Valuation and platform concerns remain: Some analysts contend that the post-announcement rally leaves ABCL approximately 33% overvalued and argue that the company’s broader antibody-discovery platform narrative is losing momentum. AbCellera also remains unprofitable, increasing sensitivity to execution and financing needs.

Analysts Set New Price Targets

Several brokerages recently commented on ABCL. Wall Street Zen cut AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Cantor Fitzgerald raised their price objective on shares of AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Truist Financial lifted their target price on shares of AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus increased their price target on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.83.

AbCellera Biologics Stock Performance

The company has a market cap of $2.99 billion, a P/E ratio of -18.07 and a beta of 1.20. The firm has a 50 day moving average price of $6.35 and a 200-day moving average price of $4.77.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. The company had revenue of $4.05 million during the quarter, compared to the consensus estimate of $7.85 million. On average, sell-side analysts forecast that AbCellera Biologics Inc. will post -0.68 EPS for the current fiscal year.

Institutional Trading of AbCellera Biologics

Institutional investors and hedge funds have recently modified their holdings of the company. AssuredPartners Investment Advisors LLC bought a new stake in AbCellera Biologics during the fourth quarter valued at about $34,000. Voleon Capital Management LP bought a new position in shares of AbCellera Biologics in the third quarter worth about $56,000. Engineers Gate Manager LP bought a new position in shares of AbCellera Biologics in the fourth quarter worth about $38,000. Allworth Financial LP lifted its position in shares of AbCellera Biologics by 857.0% during the 4th quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock worth $39,000 after purchasing an additional 10,096 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in AbCellera Biologics during the 1st quarter valued at approximately $46,000. 61.42% of the stock is currently owned by institutional investors and hedge funds.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.